Wantstats
Company ProfilePremium

Ypsomed

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
Ypsomed - Healthcare showcase

Year Founded & Workforce

2003

1,604 Employees

Industry

Healthcare

Services

YpsoMateYpsoMate 2.25VarioJectLyoTwistSmart Insulin Pen
Y

Ypsomed Employee Contacts

137 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Ypsomed Overview

Company Headquarters: Burgdorf, Switzerland

Founded: 2003

Workforce: 1,604

Company Working: Ypsomed Holding AG (Ypsomed) develops, manufactures, and sells injection and infusion systems to pharmaceutical and biotechnology companies. The three business segments of the company include – Ypsomed Diabetes Care, Ypsomed Delivery Systems, and others. The company promotes and sells its products, directly to patients or through pharmacies and clinics under the umbrella brand, mylife Diabetes care. The company offers business-to-business (B2B) to pharmaceutical companies under Ypsomed Delivery Systems (YDS). Ypsomed operates in Switzerland, other European countries, North America, and internationally.

Strategy

Ypsomed Holding AG focuses on developing technologically advanced products. The company aims to maintain and enhance customer satisfaction by providing quality products and improving customer support and services. Moreover, it aims to acquire a high level of expertise and organizational capabilities to engage in mergers and acquisitions.

Company Snapshot

$380.1M

Revenue

1,604

Employees

2003

Founded

Burgdorf, Switzerland

Headquarters

SWOT Analysis

Strengths

  • Constitutes a strong network of distributors
  • Global presence
  • Diversified product portfolio

Weaknesses

  • Less product launches related to the market in the recent years

Opportunities

  • Innovations in product development and product technology
  • Expansion with the help of strategic acquisitions

Threats

  • Government regulatory policies
  • Fluctuations in currency exchange

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
December 2018Market EntryYpsomed announced that the company, Terumo Corporation will assemble the YpsoMate prefilled autoinjector with its proprietary PLAJEX syringe for the administration of the drug Hulio. With this market entry Strategies, the company aims to strengthen its position in the market.
October 2018CollaborationThe company announced a collaboration with Royal Philips to jointly develop and deploy new digital self-medication adherence monitoring services based on Ypsomed’s connected devices and Royal Philips’ cloud-based HealthSuite Digital Platform.
August 2018PartnershipYpsomed partnered with JDRF, a global organization funding type 1 diabetes (T1D) research, to develop new technologies for next-generation automated insulin delivery (AID) systems.
March 2018Establishment of SubsidiaryYpsomed established its first subsidiary in Canada, North America. With this, the company aims to expand its presence in the market.
September 2017InvestmentYpsomed announced that it would invest around EUR 100 million for its new production site in Industrial Park of Schwerin, Germany.

Product Offering

  • Ypsomed
    • YpsoMate
    • YpsoMate 2.25
    • VarioJect
    • LyoTwist
    • Smart Insulin Pen

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 380.1 Mn in 2016 to USD 443.6 Mn in 2018.
Ypsomed — By Business Segment
Series (USD Mn)201620172018
Sales380.1455.2443.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →